| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
"IND Submission" example | IND | — | Subscribe to access the data. | Gene Therapies | Oncology | ||
"IND Submission" example | IND | — | Subscribe to access the data. | Gene Therapies | Oncology | ||
"IND Submission" example | IND | — | Subscribe to access the data. | Gene Therapies | Oncology |
Recent Updates
Recently added Catalysts
Silexion Therapeutics Corp$1.88
-0.04 (-2.39%)
Market Cap
2.09 M
EPS
-9.46
P/E Ratio
-
Value Trade
582.79 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
1.37 M
Operating CF
-3.65 M
Total Assets
4.60 M
Total Liabilities
4.31 M
Equity
291.00 K
D/E Ratio
12,345
72.41 %
Week
-50.17 %
1 Month
-68.15 %
3 Month
-80.08 %
6 Month
-99.96 %
5 Year
-99.96 %
All Time
Cash Data
Cash Position
2.41 M
Monthly Burn
1.22 M
Runway
0 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
92.15 K
52 Week Range
0.23 - 22.36
% held by Insiders
11.1 %
% held by Institutions
0.63 %
Enterprise Value
1.64 M
Total Shares
3.33 M
Short %
0.58 %
Float Shares
2.24 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Silexion Therapeutics Corp
122Total events
6Upcoming
13Tier-1 (high impact)
2023 – 2027Coverage
Upcoming catalysts 2
TBD
T2First Patient Dosed
Subscribe to view catalyst details
TBD
T3Enrollment Update
Subscribe to view catalyst details
Event history 2
TBD
▲Trial InitiationSIL-204FiledTrial
Subscribe to view catalyst details
TBD
◆First Patient DosedSIL-204FiledTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | SIL204 | IND Submission | IND | — | – | – | – |
2026-06-30 | SIL204 | IND Submission | IND | — | – | – | – |
2026-06-30 | SIL204 | IND Submission | IND | — | – | – | – |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SIL204 | locally advanced pancreatic cancer | Phase 2a | 2026-06-16 | a positive trend in comparison to the control of chemotherapy alone Read More | Silexion Therapeutics to Attend BIO International Convention 2026 Read More | |
SIL204 | locally advanced pancreatic cancer | Phase 2a | 2026-06-16 | a positive trend in comparison to the control of chemotherapy alone Read More | Silexion Therapeutics to Attend BIO International Convention 2026 Read More | |
SIL204 | locally advanced pancreatic cancer | Phase 2a | 2026-06-16 | a positive trend in comparison to the control of chemotherapy alone Read More | Silexion Therapeutics to Attend BIO International Convention 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SLXN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SLXN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SLXN▼ -34.7%on this news
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
Silexion Therapeutics has successfully initiated a Phase 2/3 clinical trial for SIL204 at Tel Aviv Sourasky Medical Center, marking a significant milestone in the program's transition to active clinical execution. The trial aims to evaluate SIL204 in combination with standard chemotherapy for locally advanced pancreatic cancer. Patient screening is expected to commence soon, with additional trial sites in Israel and Germany anticipated to join the program.
Read more →SLXNSilexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Silexion Therapeutics has received approval from Germany's BfArM to start a Phase 2/3 clinical trial of SIL204 for locally advanced pancreatic cancer. This approval follows a similar authorization in Israel, allowing the company to proceed with patient dosing in both countries. The trial aims to evaluate SIL204 in combination with standard chemotherapy, targeting a significant unmet need in oncology.
Read more →SLXN▲ +7%on this newsshared move
Silexion Therapeutics to Attend BIO International Convention 2026
Silexion Therapeutics Corp. will attend the 2026 BIO International Convention in San Diego, CA, from June 22-25. The company's management, including CEO Ilan Hadar and CFO Mirit Horenshtein-Hadar, will hold one-on-one meetings during the event. Silexion focuses on RNA interference therapies for KRAS-driven cancers and is advancing its lead product candidate, SIL204.
Read more →SLXN▼ -14.1%on this news
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
Silexion Therapeutics announced a 1-for-10 reverse share split, effective after market close on May 28, 2026, to promote compliance with Nasdaq's minimum bid price requirement. This move is aimed at reinforcing the company's capital structure ahead of a planned Phase 2/3 trial for SIL204 in pancreatic cancer. The reverse split is expected to reduce share volatility and broaden the investor base. Shareholders will see adjustments made automatically with no action needed on their part.
Read more →SLXN▼ -5.4%on this news· ran to +64% by day 3
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Silexion Therapeutics announced the approval of its Phase 2/3 clinical trial of SIL204 by the Israeli Ministry of Health, marking a pivotal advancement for the company. The Clinical Trial Application has been successfully submitted to Germany, with trial initiation expected in Q2 2026. Financial results revealed a substantial net loss and decreased cash reserves, highlighting the need for ongoing capital support. Silexion is focused on developing innovative RNA interference therapies for KRAS-driven cancers, particularly pancreatic cancer.
Read more →SLXN▼ -42.1%on this newsshared move
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
Silexion Therapeutics Corp. has announced the exercise of outstanding warrants, which is expected to yield approximately $1 million in gross proceeds. The proceeds will be utilized for general corporate purposes. The company continues to advance its oncology-focused pipeline, particularly its lead product candidate SIL204, which targets KRAS-driven cancers. The offering is anticipated to close on May 18, 2026, pending customary closing conditions.
Read more →SLXN▼ -9.3%on this news· ran to -51% by day 3shared move
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
Silexion Therapeutics has reported promising preclinical findings for its candidate SIL204 in treating KRAS-driven pancreatic cancer. The study indicated a significant increase in the expression of MHC-I in human pancreatic cancer cells with the KRAS G12R mutation. This suggests that SIL204 could enhance the effectiveness of immunotherapy by improving immune system recognition of tumor cells. The company continues to advance its clinical trials, positioning SIL204 as a potential breakthrough in the treatment of this challenging cancer type.
Read more →SLXN▼ -5%on this news· ran to -53% by day 3shared move
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
Silexion Therapeutics has initiated GMP clinical supply manufacturing of SIL204, a next-generation siRNA therapy targeting KRAS mutations, in collaboration with Catalent. The Helsinki Ethics Committee has approved a Phase 2/3 trial for SIL204 at Tel Aviv Sourasky Medical Center, marking a significant milestone in the company's clinical development. This progress reflects Silexion's commitment to advancing treatment for locally advanced pancreatic cancer.
Read more →SLXN▼ -12.8%on this news
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer
Silexion Therapeutics has successfully submitted a Clinical Trial Application for its Phase 2/3 trial of SIL204 in KRAS-driven locally advanced pancreatic cancer to Germany's BfArM. This marks a significant regulatory milestone and follows positive feedback from German authorities. The trial aims to evaluate SIL204 alongside standard chemotherapy, with plans to initiate in the second quarter of 2026.
Read more →SLXN▲ +17.5%on this news
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Silexion Therapeutics has received approval from the Israeli Ministry of Health to start a Phase 2/3 clinical trial for SIL204, aimed at treating locally advanced pancreatic cancer. This approval follows promising preclinical results and successful toxicology studies. The company plans to initiate the trial in Q2 2026 and expand development to other KRAS-driven cancers.
Read more →SLXNSilexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Silexion Therapeutics has reported its financial results for Q4 and full year 2025, highlighting substantial preclinical progress for its candidate SIL204 against various KRAS mutations. The company achieved clinical readiness milestones, including toxicology studies and regulatory submissions for upcoming trials. Financially, Silexion raised over $18.6 million during the year and regained compliance with Nasdaq listing rules. A Phase 2/3 clinical trial is planned to begin in mid-2026, targeting locally advanced pancreatic cancer.
Read more →SLXNSilexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting
Silexion Therapeutics Corp. has called for its shareholders to participate in the upcoming Extraordinary General Meeting (EGM) set for March 16, 2026. The proposals on the agenda include a significant increase in the authorized share capital and an amendment to the equity incentive plan aimed at strengthening employee and director retention. The Board encourages shareholders to vote in favor of all proposals as they align with the company's strategy to support its lead product candidate, SIL-204, and pursue future growth opportunities.
Read more →SLXN▼ -5.8%on this news
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit
Silexion Therapeutics Corp. announced participation in the 7th RNAi-Based Therapeutics Summit scheduled for January 27-29 in Boston, MA. CEO Ilan Hadar and other management will attend to engage in one-on-one meetings with stakeholders. The company is progressing its SIL204 therapy, targeting mutated KRAS oncogenes, into a Phase 2/3 clinical trial for locally advanced pancreatic cancer planned for mid-2026. Silexion is recognized as an official partner of the summit, indicating its active role in the development of RNA-based treatments for various diseases.
Read more →SLXNSilexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026
Silexion Therapeutics released a letter outlining its significant achievements in 2025 and plans for 2026, focusing on their lead asset, SIL204, which targets KRAS-driven cancers. Positive preclinical data demonstrated substantial tumor inhibition across several cancer types, leading to preparations for a Phase 2/3 clinical trial in locally advanced pancreatic cancer anticipated for H1 2026. The letter emphasized the strategic collaborations and successful toxicology studies that have positioned Silexion to tackle a significant unmet need in cancer treatment. The company views SIL204 as a promising candidate in the evolving oncology landscape, aimed at addressing broader market opportunities.
Read more →SLXNSilexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer
Silexion Therapeutics has submitted a Phase 2/3 clinical trial application for SIL204 in locally advanced pancreatic cancer to Israel. This milestone is supported by favorable German regulatory feedback and successful species toxicology studies. The trial is slated to begin in Q2 2026, with plans for regulatory filings in Germany and the EU in Q1 2026, along with potential expansion into the U.S. post-safety run-in. The initiative aims to address an unmet need in treating a challenging form of cancer.
Read more →SLXN▼ -7.6%on this news
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer
Silexion Therapeutics has received positive feedback from the German health authority regarding the design of its Phase 2/3 clinical trial for SIL204, aimed at treating locally advanced pancreatic cancer. This guidance will be incorporated into regulatory submissions planned for Israel and Germany. The company is on track to initiate the trial in the first half of 2026, pending regulatory clearance.
Read more →SLXN▲ +20.4%on this newsshared move
Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference
Silexion Therapeutics Corp. has announced its participation in the Noble Capital Markets' 21st Annual Emerging Growth Equity Conference scheduled for December 3, 2025. The company's management, including CEO Ilan Hadar and CFO Mirit Horenshtein-Hadar, will present and engage in one-on-one meetings with investors. Silexion focuses on developing innovative therapies for solid tumor cancers associated with the mutated KRAS oncogene. Their lead product candidate has shown promising results in a Phase 2a clinical trial, demonstrating positive trends compared to traditional chemotherapy.
Read more →SLXN▲ +7.6%on this news· ran to +30% by day 1shared move
Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer
Silexion Therapeutics has successfully completed toxicology studies for SIL204, a next-generation RNA silencing therapy targeting mutated KRAS oncogenes. The studies confirmed no systemic organ toxicity, allowing the company to proceed with regulatory submissions in Israel and Germany. Silexion plans to initiate a Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer by Q2 2026.
Read more →SLXNSilexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Silexion Therapeutics reported strong financial results for Q3 2025, raising over $9 million and demonstrating significant preclinical efficacy for SIL204 against various KRAS-driven cancers. The company is preparing for Phase 2/3 clinical trials, with regulatory submissions planned for late 2025 and early 2026. Additionally, Silexion has regained compliance with Nasdaq listing requirements.
Read more →SLXNSilexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer
Silexion Therapeutics has announced promising new data for SIL204, a pan-KRAS inhibitor, showing up to 99.7% inhibition across various KRAS mutations in human cancer cell lines. This includes its first evidence of efficacy in gastric cancer. The company plans to advance SIL204 into Phase 2/3 clinical trials in 2026, aiming for regulatory submissions in late 2025 and early 2026.
Read more →SLXNSilexion Therapeutics Regains Compliance with Nasdaq Listing Requirements
Silexion Therapeutics has announced that it has regained compliance with Nasdaq listing requirements, confirming it meets the minimum bid price and shareholders' equity criteria. This milestone allows the company to continue its listing on the Nasdaq Capital Market. Silexion is preparing for Phase 2/3 clinical trials for its product SIL204, which has shown significant efficacy in preclinical studies.
Read more →SLXN▲ +9.9%on this news
Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering
Silexion Therapeutics has announced the pricing of a public offering, aiming to raise $6.0 million by selling 1,500,000 ordinary shares and warrants. The proceeds will be used to advance pre-clinical studies and for general corporate purposes. The offering is expected to close on September 12, 2025, pending customary conditions.
Read more →SLXN▲ +9.9%on this newsshared move
Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration
Silexion Therapeutics announced positive preclinical data for SIL204, demonstrating its effective distribution to major pancreatic cancer metastatic sites and significant anti-tumor activity. The findings support the company's dual-route administration strategy, which combines subcutaneous and intratumoral delivery. Silexion plans to initiate Phase 2/3 clinical trials in H1 2026 following regulatory submissions.
Read more →SLXNSilexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204
Silexion Therapeutics has selected AMS Advanced Medical Services as its contract research organization to support upcoming Phase 2/3 clinical trials for SIL204, targeting KRAS-driven solid tumors. The trials are expected to start in the first half of 2026, following regulatory submissions in late 2025 and early 2026. SIL204 has shown significant efficacy in preclinical studies, including up to 97% inhibition in pancreatic cancer models.
Read more →SLXNSilexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
Silexion Therapeutics Corp. will present at the 27th Annual H.C. Wainwright Global Investment Conference from September 8-10, 2025. The presentation is scheduled for September 10 at 2:00 PM ET. The company focuses on RNAi therapies for KRAS-driven cancers and has shown promising results in its Phase 2a trial.
Read more →SLXNSilexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Silexion Therapeutics Corp. reported its financial results for Q2 2025, highlighting significant progress in its preclinical program for SIL204, an RNA interference therapy for KRAS-driven cancers. The company demonstrated high inhibition rates across pancreatic, colorectal, and lung cancer models. Silexion has entered a strategic partnership with Catalent for development support and plans to initiate Phase 2/3 trials by mid-2026. However, the company faced an increased net loss and operating expenses, raising concerns regarding its financial stability.
Read more →SLXN▼ -37.9%on this news
Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds
Silexion Therapeutics Corp. has announced the immediate exercise of warrants, generating approximately $1.8 million in gross proceeds. The funds will be used for general corporate purposes. Additionally, the company will issue new warrants as part of the transaction. This move reflects Silexion's ongoing commitment to developing RNA interference therapies for KRAS-driven cancers.
Read more →SLXN▲ +32%on this newsshared move
Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation
Silexion Therapeutics has announced promising preclinical data for SIL204, demonstrating up to 97% inhibition of pancreatic cancer cells and nearly 90% for colorectal cancer cells. The data includes significant efficacy against the KRAS Q61H mutation, marking a notable advancement in cancer treatment. The company plans to initiate a Phase 2/3 clinical trial in 2026.
Read more →SLXN▼ -8.6%on this news
Silexion Therapeutics Announces 1-for-15 Reverse Share Split
Silexion Therapeutics Corp. announced a 1-for-15 reverse share split effective July 28, 2025, in an effort to maintain its Nasdaq listing and improve its market position. Each fifteen shares will be combined into one, with adjustments for shareholders happening automatically. The company expresses optimism regarding future growth following recent progress in the development of RNA interference therapies for KRAS-driven cancers. This move is also intended to assist in compliance with Nasdaq's minimum bid price requirements.
Read more →SLXN▲ +12.3%on this news
Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines
Silexion Therapeutics has announced promising preclinical results showcasing the efficacy of SIL204 in human lung cancer cell lines with KRAS G12D mutations. The company plans to conduct additional studies on a new KRAS mutation, which could further solidify SIL204's role as a pan-KRAS treatment. With plans for a Phase 2/3 clinical trial set to commence in Q2 2026, Silexion continues to explore SIL204's potential across multiple KRAS-driven cancers. These findings underscore SIL204's innovative RNA interference technology and its ability to target cancer drivers at the genetic level.
Read more →SLXNSilexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers
Silexion Therapeutics has announced compelling preclinical results for its RNA interference therapeutic candidate, SIL204, which shows strong efficacy against pancreatic, colorectal, and lung cancers. The study reports significant inhibition of cancer cell proliferation and metabolic activity, particularly through observed effects on KRAS G12D mutations. Encouraging results include a 90% inhibition rate in colorectal cancer cell lines. The company plans to conduct further studies to explore SIL204's impact on lung cancer treatment, marking a significant advancement in targeting KRAS-driven cancers.
Read more →SLXNSilexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer
Silexion Therapeutics has completed key preclinical studies on SIL204, assessing its potential therapeutic impact on colorectal and lung cancers, alongside pancreatic cancer. The studies analyzed the candidate's effectiveness against cancer cell lines with KRAS mutations, revealing promising opportunities in a market worth over $30 billion. Company leadership views this milestone as crucial for expanding their development strategy. Comprehensive results are expected to be announced soon, which could influence future directions for the company.
Read more →SLXNSilexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Silexion Therapeutics Corp. reported its first quarter 2025 financial results, highlighting significant progress in its SIL204 program for KRAS-driven cancers. The company announced promising preclinical data showing substantial reductions in tumor burden and metastasis. Further, Silexion solidified its financial footing through successful financing activities, allowing for the expanded dual-route development strategy for SIL204. Operating losses, however, have increased relative to the previous year, indicating potential concerns about sustainability amidst growing operational costs.
Read more →SLXN▲ +46.5%on this news
Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities
Silexion Therapeutics has announced a strategic collaboration with Catalent to advance the development of its siRNA candidate, SIL204. This partnership will focus on formulation development and clinical manufacturing, aiming to optimize the delivery of SIL204 for treating KRAS-driven cancers. The collaboration follows positive preclinical results indicating SIL204's effectiveness in reducing tumor growth and metastatic spread. Silexion plans to initiate human clinical trials in 2026, with ongoing studies and regulatory submissions underway throughout 2025 and into 2026.
Read more →SLXNSilexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
Silexion Therapeutics Corp. has unveiled an expanded development plan for its siRNA candidate, SIL204, targeting KRAS-driven pancreatic cancer. This decision follows promising preclinical findings that indicate SIL204 can significantly inhibit tumor growth and reduce metastases. The dual administration approach aims to enhance treatment efficacy while Silexion prepares for human trials set to begin in early 2026. The company is also planning regulatory submissions in Israel and the European Union for advancing clinical development.
Read more →SLXNSilexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference
Silexion Therapeutics has completed an expanded development plan for its siRNA candidate SIL204, aiming to address KRAS-driven cancers. The plan builds on recent positive preclinical findings, which will be presented at the NeauxCancer Conference in New Orleans, March 27-29, 2025. The company's CEO expressed optimism about leveraging these findings to advance SIL204 towards clinical development. Silexion also offers one-on-one meetings for investors during the conference, emphasizing its commitment to innovative oncology therapies.
Read more →SLXNSilexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Silexion Therapeutics Corp. has reported its financial results for 2024, showcasing significant progress in both its clinical pipeline and its business operations. Highlights included breakthroughs for its candidate SIL204 in preclinical models of pancreatic cancer, a completed merger enhancing capital access, and promising results for its initial product, LODER. However, the company also reported an increased net loss and rising operating expenses due to its transition to a public entity. With a strengthened financial position after recent funding, Silexion aims to advance its clinical trials and explore additional cancer treatment applications.
Read more →SLXN▲ +30.6%on this news
Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models
Silexion Therapeutics has announced positive results from studies using SIL204 for treating pancreatic cancer in orthotopic models. This approach showed a significant reduction in both tumor growth and the spread of metastases, suggesting SIL204's potential for systemic delivery. The results indicate a promising future for SIL204 as a therapy for KRAS-driven pancreatic cancers, setting the stage for an expanded development plan. The findings are particularly significant as they demonstrate effective treatment in a model that closely mimics human disease.
Read more →SLXN▲ +64%on this news
Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204
Silexion Therapeutics has completed its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This study focused on SIL-204's efficacy in reducing primary tumor growth and metastatic spread. The use of orthotopic models, which mimic the natural growth environment of pancreatic tumors, provides valuable insights for the therapy's potential applications. Silexion plans to report initial data results in March 2025, which will inform its development strategy for SIL-204.
Read more →SLXN▲ +132.6%on this news
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
Silexion Therapeutics Corp. announced the exercise of warrants for an aggregate of $3.3 million in gross proceeds. This move involves the immediate exercise of outstanding warrants for purchasing up to 2,221,523 ordinary shares at an exercise price of $1.35 per share. The proceeds will be utilized for general corporate purposes, highlighting the company's commitment to advancing its pipeline of RNA interference therapies for KRAS-driven cancers. The offering is expected to close on or around January 30, 2025. Silexion continues to push the boundaries of therapeutic innovation in oncology.
Read more →SLXN▲ +132.8%on this news· ran to +441% by day 1shared move
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
Silexion Therapeutics announced promising preclinical results for SIL-204, a next-generation siRNA therapeutic targeting KRAS mutations in pancreatic cancer. The findings demonstrate a ~50% reduction in tumor growth in mouse models, highlighting the effectiveness of systemic administration methods. The company plans further studies to assess the treatment's impact on metastases and to refine its development strategy. This positions SIL-204 as a potential breakthrough in KRAS-driven cancer therapy, subject to successful clinical validation.
Read more →SLXNSilexion Therapeutics Announces Pricing of $5.0 Million Public Offering
Silexion Therapeutics Corp has announced the pricing of a public offering, set to raise approximately $5.0 million through the sale of shares and warrants. The offering price is set at $1.35 per share, with the funds intended to support the company's ongoing preclinical studies and general corporate purposes. The offering is anticipated to close around January 17, 2025, subject to customary conditions. Silexion is focused on developing RNA interference therapies for cancers driven by KRAS mutations and aims to innovate in oncology treatment.
Read more →SLXNSilexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies
Silexion Therapeutics has announced new preclinical data indicating that its RNAi therapy, SIL-204, demonstrates significant synergistic effects when combined with standard chemotherapy agents for pancreatic cancer. The preclinical results reveal enhanced efficacy against human pancreatic tumor cell lines with KRAS mutations, showcasing a notable reduction in cancer cell confluence when SIL-204 is used alongside 5-fluorouracil and irinotecan. Following successful preclinical findings, the company plans to advance SIL-204 into clinical trials for locally advanced pancreatic cancer by 2026.
Read more →SLXNSilexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium
Silexion Therapeutics Corp. will present data on SIL-204, an RNA interference therapy targeting KRAS mutations, at the 2025 ASCO Gastrointestinal Cancers Symposium. The symposium, held in San Francisco from January 23-25, aims to showcase advancements in gastrointestinal cancers. Silexion's abstract will be available prior to the presentation on January 21, and the company's innovative approaches focus on improving outcomes in challenging cancer types.
Read more →SLXNSilexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
Silexion Therapeutics has announced an ongoing collaboration with Evonik to develop an advanced siRNA formulation to improve cancer treatment outcomes. The partnership utilizes Evonik's biodegradable microparticle technology for Silexion's candidate SIL-204, which has shown promising preclinical results against KRAS-driven cancers. This collaboration aims to enhance the stability and targeting of RNAi therapies, addressing one of oncology's most significant challenges. However, the company acknowledges various risks and uncertainties regarding the future success of its projects.
Read more →SLXNSilexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors
Silexion Therapeutics has appointed Prof. Amnon Peled, a recognized expert in cancer therapeutics, to its Board of Directors. His extensive experience in stem cell biology and oncology is expected to strengthen the company's development of RNA interference therapies for KRAS-driven cancers. Prof. Peled will also serve on key board committees, ensuring compliance with regulatory requirements. His involvement comes at a crucial time as Silexion aims to advance its therapeutic pipeline and deliver innovative solutions in oncology.
Read more →SLXNSilexion Therapeutics Announces 1-for-9 Reverse Share Split
Silexion Therapeutics Corp. announced a 1-for-9 reverse share split in an effort to maintain its listing on the Nasdaq. This will be effective after market close on November 27, 2024, with trading on a split-adjusted basis commencing on November 29, 2024. The CEO emphasized that this move is part of a strategy to ensure long-term growth and manage share price volatility. The company believes this decision will help align with Nasdaq standards, enhancing its position for future equity financing.
Read more →SLXNSilexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference
Silexion Therapeutics Corp. is set to present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference on December 4, 2024. CEO Ilan Hadar will discuss the company's innovative RNA interference therapies aimed at treating KRAS-driven cancers, with a focus on pancreatic cancer. The event will also include opportunities for one-on-one meetings with interested investors. Silexion is known for its promising Phase 2 trial results of its product LODER™ and its development of the next-generation siRNA candidate, SIL-204.
Read more →SLXNSile ncing Oncogenes at the Level of Gene Expression Nasdaq: SLXN Corporate Presentation September 2024 The statements contained in this presentation that are not purely historical are forward - looking statements . Our
Silexion is advancing its siRNA platform technology aimed at silencing oncogenes, with a focus on treating KRAS-driven cancers. Following a Phase 2 trial that demonstrated a 9.3-month improvement in overall survival, the company's next steps include moving its lead candidate SIL-204 into Phase 2/3 trials targeted at locally advanced pancreatic cancer. However, Silexion faces challenges, including a lack of revenue, limited operating history, and the unproven nature of its therapeutic approach. The company's future success will depend on the results of forthcoming clinical trials and its ability to attract necessary personnel.
Read more →SLXNSilexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference
Silexion Therapeutics Corp. will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York. The company management will be available for one-on-one meetings with investors. A company presentation will be available on demand starting September 9, emphasizing Silexion's focus on innovative oncology treatments, particularly for solid tumors with the mutated KRAS oncogene. Previous clinical trials have demonstrated encouraging results for Silexion's lead product candidate.
Read more →SLXN▲ +7.6%on this news
SILEXION THERAPEUTICS LTD. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 SILEXION THERAPEUTICS LTD. INTERIM FINANCIAL STATEMENTS JUNE 30, 2024 (Unaudited) TABLE OF CONTENTS Page CONSOLIDATED FINANCI
Silexion Therapeutics Ltd. has released its unaudited interim financial statements for June 30, 2024, revealing a notable decline in its financial position. The company's total assets have decreased sharply, leading to an accumulated deficit of nearly $30 million. In the last quarter, Silexion reported a net loss of approximately $2.9 million, with liabilities surpassing assets, indicating potential financial challenges. Overall, the figures suggest a struggling operational performance and heightened financial risk for the company.
Read more →SLXNSilexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination
Silexion Therapeutics Ltd., an oncology-focused biotechnology firm, has successfully completed its business combination with Moringa Acquisition Corp, resulting in the formation of Silexion Therapeutics Corp. The new entity's ordinary shares and warrants are set to commence trading on Nasdaq shortly. This transition is viewed as a major milestone for Silexion, enabling enhanced strategic and financial capabilities to advance their oncology-focused projects. While the company aims for innovation in cancer therapies, it also faces challenges related to market competition and operational growth.
Read more →SLXNSilexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp
Silexion, an oncology-focused biotechnology company, is set to become publicly traded through a business combination with Moringa Acquisition Corp. The deal, valued at $62.5 million, follows positive results from Silexion's Loder in a Phase 2a clinical trial for non-resectable pancreatic cancer. Both companies are optimistic about the merger, with expectations to finalize the agreement by the third quarter of 2024, pending shareholder and Nasdaq approvals. However, the transaction faces potential risks related to its completion and investor commitments.
Read more →Competitive Position
How SLXN ranks across every disease it competes inCompetitive Position is a premium feature
See how SLXN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial